Reata Pharma (RETA) |
|
28.74 0.61 (2.17%)
|
01-16 05:29 |
|
Open: |
27.8 |
Pre. Close: |
28.13 |
|
High:
|
28.88 |
Low:
|
27.24 |
|
Volume:
|
393,889 |
Market Cap:
|
1,046M |
|
|
|
|
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
28.921 - 29.083 |
29.083 - 29.231 |
|
Low:
|
26.825 - 27.031 |
27.031 - 27.219 |
|
Close:
|
28.43 - 28.74 |
28.74 - 29.024 |
|
Technical analysis |
as of: 2022-01-15 8:49:19 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 37.19  One year: 43.44 |
| Support: |
Support1: 27.63 Support2: 25.02 |
| Resistance: |
Resistance1: 31.84 Resistance2: 37.19 |
| Pivot: |
27.89 |
| Moving Average: |
MA(5): 28.65 MA(20): 28.04
MA(100): 80.15 MA(250): 101.97 |
| MACD: |
MACD(12,26): -6.71 Signal(9): -9.03 |
| Stochastic oscillator: |
%K(14,3): 50.44 %D(3): 53.26 |
| RSI: |
RSI(14): 32.10 |
| 52-week: |
High: 153.41 Low: 25.02 Change(%): -74.1 |
| Average Vol(K): |
3-Month: 85242 10-Days: 71642 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.RETA has closed below upper band by 33.5%. Bollinger Bands are 78% narrower than normal. The narrow width of the bands suggests low volatility as compared to RETA's normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 11 Jan 2022
Reata Pharmaceutical's build-to-suit HQ at 6100 Legacy Drive hits sublease market, according to sources - Dallas Business Journal - Dallas Business Journal
Fri, 07 Jan 2022
Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ... - Yahoo Finance
Tue, 04 Jan 2022
Bronstein, Gewirtz & Grossman, LLC Reminds Reata Pharmaceuticals, Inc. (RETA) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire
Mon, 03 Jan 2022
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 18, 2022 - RETA - PRNewswire
Mon, 03 Jan 2022
RETA INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm's Attorneys, Securities Fraud Class Action Pending - GlobeNewswire
Fri, 31 Dec 2021
Reata's Advisory Committee Hiccup Ruins Its Future Prospects - Seeking Alpha
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
31 |
| Shares Float (M) |
30 |
|
% Held by Insiders
|
4.74 |
|
% Held by Institutions
|
85.89 |
|
Shares Short (K)
|
4,220 |
|
Shares Short P. Month (K)
|
4,080 |
Stock Financials |
|
EPS
|
-7.740 |
|
EPS Est This Year
|
-1.760 |
|
EPS Est Next Year
|
-2.200 |
|
Book Value (p.s.)
|
7.030 |
|
Profit Margin
|
|
|
Operating Margin
|
-1651.90 |
|
Return on Assets (ttm)
|
-21.1 |
|
Return on Equity (ttm)
|
-125.7 |
|
Qtrly Rev. Growth
|
427.6 |
|
Gross Profit (p.s.)
|
-4.768 |
|
Sales Per Share
|
0.437 |
|
EBITDA (p.s.)
|
-7.180 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-158 |
|
Levered Free Cash Flow (M)
|
-8 |
Stock Valuations |
|
PE Ratio
|
-3.71 |
|
PEG Ratio
|
|
|
Price to Book value
|
4.09 |
|
Price to Sales
|
65.78 |
|
Price to Cash Flow
|
-5.73 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
